#synchrotronscience New insights to advance targeted brain cancer therapy 🔬 A research team has come together to successfully synthesize and characterize nanocarriers for the drug #riluzole which has been proved biocompatible with #glioblastoma cells 🔗 https://lnkd.in/dbEcYZry
ALBA Synchrotron’s Post
More Relevant Posts
-
Pushing the boundaries in brain cancer therapy: Unveiling Tyrosine Kinase Inhibitors for glioblastoma. Targeting the enzymes that signal cancer growth, TKIs offer a sharp attack on malignant cells, sparing the healthy ones. Marking progress with potential to enhance with chemo or radiation, this strategy is rewriting the glioblastoma battle plan. Discover this clinical trial's journey at medohhealth.com #BrainCancerInnovation #GlioblastomaTreatment #TKITherapy #CancerResearchAdvances #HealthcareBreakthrough #MedohHealth #ClinicalTrialsJourney #OncologyProgress #CancerCareFuture #MedicalScienceUpdates
Tyrosine Kinase Inhibitors
To view or add a comment, sign in
-
Updates From the #FDA: The PD-L1 IHC 22C3 pharmDx companion diagnostic tool is now FDA-approved in gastric or GEJ adenocarcinoma, FTD granted to SONALA-001 + INSIGHTEC Exablate 4000 Type-2 Device for the treatment of patients with rare brain cancer. #gicsm 1. https://lnkd.in/gAvJVMpN 2. https://lnkd.in/gshAPMs2
To view or add a comment, sign in
-
Journal of Cancer Therapy and Research Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Submit your related work at: cancer@genesispub.org Kindly visit our journal homepage: https://lnkd.in/dJe3Huxs #renalcancer #oncology #cancerresearch #submitmanuscript #doctors #researchers
To view or add a comment, sign in
-
For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care. #MolecularTumorBoard #PrecisionOncology #CervicalCancer
To view or add a comment, sign in
-
SALES EXECUTIVE - BUSINESS DEVELOPMENT - RELATIONSHIP MANAGEMENT - OPERATIONS LEADERSHIP - ELEVATING BUSINESS PERFORMANCE - EXPEDITING GROWTH AND PROFITABILITY
For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care. #MolecularTumorBoard #PrecisionOncology #CervicalCancer
Molecular Tumor Board: 39 year old female with history of advanced stage squamous cell cervical cancer, new lung mass and PIK3CA mutation | Labcorp Oncology
learn-more.com
To view or add a comment, sign in
-
Central Laboratory Services | Non-Clinical | Clinical Phase I-IV | Preclinical | Early Development | Biomarkers | Business Development | Inside Sales
For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care. #MolecularTumorBoard #PrecisionOncology #CervicalCancer
Molecular Tumor Board: 39 year old female with history of advanced stage squamous cell cervical cancer, new lung mass and PIK3CA mutation | Labcorp Oncology
learn-more.com
To view or add a comment, sign in
-
For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care. #MolecularTumorBoard #PrecisionOncology #CervicalCancer
Molecular Tumor Board: 39 year old female with history of advanced stage squamous cell cervical cancer, new lung mass and PIK3CA mutation | Labcorp Oncology
learn-more.com
To view or add a comment, sign in
-
A new study offers hope for thousands impacted each year by aggressive brain cancer, glioblastoma. Scientists at the University of Sussex led an international research team to understand the possible reasons for resistance to treatment drugs, helping to guide future therapies to improve quality of life and increase life expectancy for those with glioblastoma. In the study, published in the journal of Advanced Science, researchers have discovered that an understudied protein, called PANK4, is able to block cancer cells from responding to chemotherapeutic treatment for the highly intrusive brain cancer. #ResearchWithImpact https://ow.ly/f4PY50QF4as
To view or add a comment, sign in
-
Discover how the IVIS Lumina system is revolutionizing cancer research! A recent study showcases its use in tracking hypoxia and angiogenesis in cervical cancer, providing real-time validation and monitoring with unmatched precision. Paper link: https://lnkd.in/g_i-_ERX #revvity #fluorescence #bioluminescence #IVIS #Opticalimaging #preclinical
To view or add a comment, sign in
-
For patients who present with advanced stage cervical cancer, targeted therapies can improve outcomes. Join us for a molecular tumor board as we discuss treatment options for patients with recurrent cervical cancer and how biomarker-directed therapies are transforming the standard of care. #MolecularTumorBoard #PrecisionOncology #CervicalCancer
Molecular Tumor Board: 39 year old female with history of advanced stage squamous cell cervical cancer, new lung mass and PIK3CA mutation | Labcorp Oncology
learn-more.com
To view or add a comment, sign in
8,493 followers